Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Glenfidrich - it really doesn’t matter about your loose definitions of a “trader” or “investor” . The key thing is both are here to make money - plain and simple. I don’t think anyone here is on a philanthropic journey. What are you talking about “wetting the bed” and “just chill”. I have a significant sum invested and I’m not one of those white knuckle holders which many here profess to but I’m not a day trader either. For those who missed the opportunity of last massive rise - learn from your mistakes. The lth crowd in my view have a flawed strategy and demonstrated their investment failure by holding through a period of huge increase and now hoping and wishing for a similar rise.
Whilst I agree with the latter part of your post, I do disagree with the formative part of it.
An investor is simply someone that purchases something with the expectation or hope that it increases in value. Who receives the funds does not differentiate one between an investor or a trader. If you invest in wine, you don’t have to buy it from the maker. If you invest in old coins, they don’t have to come from the mint. If you buy an E-Type, you don’t have to buy it from Jaguar etc.
Technically you are only an investor if you buy shares in a placing or the wrap earlier this year. Any other buys, even if you hold for a long time is a trade. Your trade don't do anything for company. You can only utter the phrase, I pay the boards wages if you buy in a placing. Doesn't stop lots of posters saying it though.
Slam, I've been here for more than 10 year. I trade and hold. I've sold our completely twice. One time I bought back in within days. Even with recent buying im still just about on a free ride for 80k shares. I'm in my longest buy/hold period I ever done right now. I will keep buying until a pound.
I'm sorry but I have to ask this question.
What is there that stops you from being a Trader and a LTH in the same stock - doesn;t that give you the best of both worlds?
As a LTH you watch this stock on a daily basis - you know its "ins and its" outs. As a LTH you know the Company intimately and you understand the nature of its "ups and downs". As a LTH you believe in the COmpany and you believe in the long term rewards of holding the Stock.
But, why oh why, can;t you trade in it too. Sure - keep a core holding that will benefit from those long term rewards. BUT.... you also know so much about the company and the idiosyncracies of the AIM Market that you are some of the best minds to make even more money by trading the stock on top of your core holding.
But please stop whining about the difference between a trader and a LTH.
Started: carter19, 20 Jun 2024 12:38
Last post: dramallama, 20 Jun 2024 17:14
I’m just happy to be able to get my average down, from 260 to 43p so far
Not all of the red trades are sells as we all know. Buyers want the shares cheaply so will always put in a low price. MMs obviously happy to oblige.
Just the way that it is
I don't agree. I'm very disappointed with the decline of the SP. It's always the same with Sareum.
In my opinion, I think it’s holding rather well.
Laz - I’m sure there will be traders who will buy in, just wonder if there will be the volume to push up. Despite us being in a great space with our compound and up to date positive signals from Tim, we just aren’t getting the momentum to break out. I know the evangelicals here will pour scorn on anything but dreamy comments but the reality currently is a near 20% drop in the last couple of weeks (still 300% above 10p buy in though) Interesting thing is apparently everyone is still buying and “topping up”. - Quick Look at trades and the sea of red says otherwise for today
Started: HotblackDesiato, 18 Jun 2024 18:37
Last post: Gunner68, 20 Jun 2024 10:47
I agree with you potnak 1802 once/if 1801 is validated with low tox and potential to be best in class we would definately see more interest especially if 1802 indications are for cancer I wonder if there would be combo trials which seems to be the way forward
GLA
Hi Krusty, I have always wanted SAR to go for P2 on their own but the only option for funding would mean dillution for existing shareholders and personally I'm throwing any more large sums at this. I am still buying but it's only disposable income each month. I really do think the board need to step up and prove they can negotiate a deal for 1801. The business model is and has always been to licence at pre or early clinical stages. Thats where we are right now. Any pharma will know the cash runway is getting shorter so I don't think we are in a great negotiating position so upfront might be where we have to compromise. However, if 1801 is with a n other pharma then even a modest upfront of say £5 to £10 million will be enough to get 1802 ready for trials. That would, for me be an amazing deal. The biggie has always been 1802.
Well each day with no update provokes more small lot selling which gives MMs just the reason they need to lower the price
I would prefer not to receive good news when the share price has sunk into the 20s
(and no, this isnt any kind of deramp)
You're spot on Lsesar. One day all the talk of "the science" and the much expected positive RNS may happen hopefully we will have some cash left in here to benefit from it.
Bobbler - I’m conveying where I am with the whole rns release we are all waiting on - not de-ramping
This is one of your posts:
“If it spikes at £10 there will a lot of people with a serious spike in their blood pressure!”
Would this be considered a ramping attempt? Sure I told you before filter me, or if that’s not working just ignore me please.
Started: sadoldgit, 20 Jun 2024 08:31
Last post: sadoldgit, 20 Jun 2024 08:31
Started: sadoldgit, 19 Jun 2024 15:29
Last post: sadoldgit, 19 Jun 2024 15:29
Have posted before but the link indicates the areas and competition that we face.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959504/
Thanks for the clarification Billy - Good luck whatever you decide
Good luck, Billy. Looks like you are timing it right. I thought we might see a blue day today, in case of a Thursday RNS. If not Friday might see a drop.
Lazarus2 and Potnak, that buy wasn't me. I'm hovering with £40K to spend here, just waiting to see if the share price has settled or if it going to drop any further before I pull the trigger.
Bill
Yeo, Billy, don't want out him but he is probably the biggest investor here. He holds more than the the board members.
I think you are correct Potnak. It was Billy that stated he was buying I believe. Credit to him.
Started: Brighty1, 19 Jun 2024 07:46
Last post: steve196, 19 Jun 2024 10:48
Any idea how much their average is now 🤔
They did.
What I don't understand is, why don't HNWI average down when it was around the 10p mark.
It will be along time before it's get to their buy in price.
Unless the trails are excellent.
If the compound and 1a data is good, we won't need HNWI investment and the dillution that brings. We should get a licenced, as per the RNS.
If the compound and 1a data is good. We won't n
Started: sadoldgit, 19 Jun 2024 08:03
Last post: sadoldgit, 19 Jun 2024 08:03
Interesting link below. Good for overview
https://www.linkedin.com/pulse/baricitinib-market-global-outlook-forecast-2022-2028-share/
Unfortunately it does not give any indication of dollar revenues.
In a separate link.
Deucravacitinib generated 66 million dollars in the last quarter of 2023. 62 million of this was in the US.
This equates to approx 250 million dollars a year, not bad for an inhibitor that can be bettered in efficacy for Psoriasis and duly failed to meet either of its 2 end points in Ulcerative Colitus
It is very difficult to try to establish any ball park figure of a potential value for 1801 as we need some idea of potential Indications.
We should be able to better Baricitinib in at least regards to SAE's
Interesting also to note that Baricitinib was also hailed as the first and only kinase inhibitor NDA approval for covid19.
Regards
Last post: Celtic007, 18 Jun 2024 19:32
So it went up, it’s gone down. We’re waiting for news. Got it. Some thing never change but glad to see a few familiar faces
Welcome back Hopkirk
KR
ZA
Tricky, your lack of punctuation, seriously lol
Good to have you back! Really 4 years wow where has time gone. I hoped to be sold up by now.
Welcome back
Nice to see you post again Hoppy.
Hopefully we are on the verge of a very positive RNS
Started: Lazarus2, 18 Jun 2024 09:49
Last post: The-Oracle, 18 Jun 2024 17:18
Or they might just take a portion of their salary come payday next week and pile in.
47 to 30 is nothing against results.
Crap results and it's a loss.
Excellent results as we hope and expect and it's to the moon. Sareum has done it before, we are further ahead and can do it again. If it's delayed by 2 weeks eg, it means nothing. Probably the T's and I's because someone fell ill. If they have the results, they have to Rns, if they don't, the results are neither good nor bad, just unknown.
Sell, buy or hold, or overfocus on SP that has nothing on the results. Could be a loss either way. Sell and wake up to 100 and hate yourself, buy and wake up to 0.05 and hate regret. Gl
If you want to sell, just do it. People are waiting to buy in lower. I will top up in 2 days if no Rns and the price is right.
If, ifs and buts were pots and pans, you wouldn't need a tinker man.
This time next year Rodney.
Sorry for incomprehensible posts. A mixture of predictive texts and a phone screen that is starting to die, I think.
If no news next week. I think some holders will get itchy feet, especially if they bought around 10p. The drop from 47p is already a bitter pill to swallow and I think we have lost some if the new investors already. It certainly doesn't is, quieter in this group. Having said all that. I've go a feeling that we will get something this week.
Do you mean"no red days after that" ?
Started: sadoldgit, 18 Jun 2024 10:00
Last post: lutonnews, 18 Jun 2024 12:19
don't worry
the sar rocket is being primed ready for launching at a secret location not far from the portobello road.
doc holliday and mr o are among the crew. just waiting for a red dot to ignite the lift off.
what could possibly go wrong ?
oh eck, i have just seen higgs climb into the ****pit.
Welcome to sareum.
Always drops between news.
Often doesn’t recover fully, too.
Aber - I can assure you that it is not Ostrich mentality. The next news will be the Trial results. You obviously know that. (unless 737 comes in from left field which I doubt)
If you are here as a bit of a flutter then fine. I have made my position and views clear. It is not advice, just a personal view based on believing in what Sareum are trying to achieve as opposed to what the spivs would have us believe. Good luck anyway
47p a couple of weeks ago now down to 32p today... I know some are saying follow the science and don't worry about the SP ... but that is ostrich mentality !! ... It is better to have an elevated SP prior to news if we want a higher SP after news
We need some form of news inbound ... I hope the silence is down to the BOD working on deals in the background, especially as TM and JR are being paid almost £20K each per month !!! and Parker £10K
Woodlands that should have read, apologies.
Must be a massive sale early this morning, or last night. Couldn't buy under 37 yesterday.
All will be revealed in time.
Last post: sadoldgit, 17 Jun 2024 19:34
Of course shares can go up and down and that is stating the obvious.
However he is also stating what he thinks may happen on the receipt of a poor phase1 trial RNS.
That is not quite the same.
At the moment he is not invested.
Essentially he was saying shares can sometimes go up or down……very profound
Krustysmegma,
I am inclined to agree with you very strongly. Perhaps it is not the most ill informed, but contrived yo serve a purpose.
What is the posters objective for posting such a post.
Primarily he has no shares at the moment and yet states it will buy back if the news is good.
However, which way we look at it, it is somebody who intends to buy back in.
On the release of good news this individual will need to be quick as will rise like a rocket.
As for any bad news, I ask the question on what factual or indeed basis of debate postulate that we may recieve bad news?
What would be the cause?
Tim and Co extremely confident of good results.
Mentions of best in class.
Very good at chemistry they are. Very experienced. I would definitely take that as a very positive indication, as to the success of 1801 data results, over and above the unsubstantiated drivel posted here..
Regards
Been hybernating until trial results - sometime soon I think - but are we expecting a big chunk of cash from CR fund too?
I think in all my years of reading posts on this board, this one might be the most ill-informed, badly thought through I've ever read. This has been posted by someone who clearly doesn't have a clue about SAR, or done the most basic research, and who has a strategy that is guaranteed to fail. Anyway, good luck, hope it works out for you after all your hard work.
Started: Silverfoil13, 16 Jun 2024 22:50
Last post: Lsesar, 17 Jun 2024 15:54
Bobbler - ramblings yeah ok, multiple personalities yeah ok, contradictory views in one post yeah ok…. And… now what. Just filter me please. I can’t do the unabated enthusiasm which some have here. Sareum can be summed up nicely by Gattuso “ Sometimes maybe good, sometimes maybe ****”
I certainly can't disagree with the good strategic planning.
Without wishing to appear overly blunt the BoD cannot see past the end of their noses. Add a splash of naivety and hey ho we were in a severe mess, nigh right up 5hit street Without a paddle.
Now fortunately we are recovering
Clearly the BoD have not looked far enough into the future. Have coped before in a buoyant market but from Feb 22 difficulties with financing rose.
On the plus side we don't appear to have any problems with adverse events.
The only indication we have at the moment is Psoriasis. Should be able to better Deucravacitinib in the PASI 75 score.
Looking at achieving better score over 12 weeks than Deucravacitinib over 16 weeks, with of course similar tolerability and safety profile.
This is about all we can say we nigh have under the belt at the moment.
Finance of some sort will be needed and Sareum look to be pursuing non dilutive means.
Phase 1 results will see a rise in my opinion. Accessing likely non dilutive funding and details therefore will at the very least maintain SP climb until further positive news.
On no news of non dilutive funding the SP likely to follow the trajectory that has occurred in the past and a slow retrace.
My own opinions of course.
There is a lot l believe going on which the BoD either can't or won't let on.
The good old days of the transformational change that did no quite materialise where the Sp dropped around 60 % max on the day.
Tim got slated for this hence now there exists silence.
Regards
Psoriasis Deucravacitinib is available as a treatment on the NHS it is also available to purchase.
The ramblings of someone with multiple personalities. Not sure if you could get anymore contradictory views into one post!
SOG - Very interesting read. Looking at the reasons why drugs fail:
Analyses of clinical trial data from 2010 to 2017 show four possible reasons attributed to the 90% clinical failures of drug development: lack of clinical efficacy (40%–50%), unmanageable toxicity (30%), poor drug-like properties (10%–15%), and lack of commercial needs and poor strategic planning (10%)
We appear to have very low toxicity indicated but I don’t think we have good strategic planning (sorry bod don’t inspire me when it comes to business savvy). Clinical efficacy will begin to be demonstrated in phase 2 on ward.
Those who have the stomach to continue to hold for the next rns on phase1 results stand to see a l least 100% rise from todays price if positive (could easily be more dependant on if the bod have a deal).
Those who wish to bail, jump -if it come good best of luck just trying to get back in at todays prices, it will be a multiple of todays 40p
Those who are holding , hold - just try to sell quickly if it’s negative news, Sub 1p easily achievable
Potnak you are not very scientific, or have any scientific understanding which is confirmed by the gibberish you write at times.
You state one moment that we all need to understand that there is a 75% failure rate in Phase 1 trial, based on something you seemed to have read. Then you follow up with you seemed to remember reading about 75% of drugs never get past phase 1.
Without wishing to appear pedantic which of the two statements you made are true.
You based your first statement as fact. The 75% failure rate in phase1.
This is clearly incorrect as l have pointed out and given guidance for further info to peruse.
As for not going to read it all? Why not?
All you in effect do is feed the negative numpties over on ADVN with a source to undermine.
I have never picked on a poster that has demonstrated even the slightest scientific knowledge.
I did an OU Science degree many moons ago, I worked in engineering in the early part of my career.
At the age of 24 l was a field service engineer installing, repairing and retrofitting corrugated cardboard manufacturing equipment weighing anything up to 200 tonnes.
I worked nigh 3 years on research and development in engineering.
An enjoyable at times job but difficult when on your own.
99% of any investigational work carried out is down to precision and accuracy. Each individual component needs an understanding of its strong points and weak points.
Almost good enough is never good enough, hence failure.
There is no intention from me to stamp my superior knowledge on anybody.
What l will do is challenge statements that are not only false and misleading but also unsubstantiated with no proper resource to back it up.
With regards to not posting anything negative, l will be diplomatic and say you have not posted anything positive either.
My opinion for what it is, is that you are trading at the moment. I have nothing against this.
What l am against is up and down posting. One minute pointing out 1 to 2 billion company value at one time then introduce 75% risk of failure on the other hand.
You sir, are unbalanced to say the least.
I am 100% certain in the belief that the outcome will prove satisfactory for further trial such as phase2a, what l am not 100% certain about is the full scope of side effects or the full data results of biomarkers.
These will have significant effects as to the value of SDC1801.
Regards and enjoy a couple of days off.
Started: colbaltblue, 17 Jun 2024 12:43
Last post: Aberystwyth, 17 Jun 2024 14:49
Many Thanks Ronnie - much appreciated
Cobalt. Bottom left, tap 'cookies' then turn off all concents, go right down the page and agree, or whatever it says...... and most of the carp adverts will disappear.
Stop? Will there be any FOMO? At this rate we'll be lucky to get back to 50p. Will my screen ever stop jumping about or be filled with carp adverts?
Is this ever going to
Last post: sadoldgit, 17 Jun 2024 10:14
Unfortunately it does not quite work like that tricky.
It would be good if it did.
Regards
If we have a few more buys than sells and we will jump 5%
Got to work both ways 🤪
Last post: sadoldgit, 17 Jun 2024 07:16
Funny Guy on what factual basis do you make such absurd statements.
What has notification of the on licensee to do with SRA737 advancement.
As for 182 it does not exist.
1801 we await final data analysis results. Could be tomorrow next week or next month. Bit it will come and the Indications are it will prove successful.
SDC1802 whilst being developed in preclinical stage for oncology there have been recent patent applications for 1802 to be used as am immunotherapy. Clearly there is significant benefit here.
If you doubt this then please provide satisfactory evidence to substantiate your statement.
Next thing you will be stating is this will be going down to 10p again as you have proven history of.
Regards
There is no cat in hell chance there will be an imminent notification of SRA 737 advancement, they have not even said who the license is with and very little if any money has been paid.
There is very little chance of a license for 182
i think people are really jumping the gun
HBD, I do not think they would have agreed the new licence without a belief that 737 would be progressed, they are motivated by both finding solutions for this terrible condition (I know from posts that this was of the reasons for investment as well as looking to make a return, this was certainly one of my non financial reasons for investing)and generating more money to invest in research. On 737 I choose to believe that we will get real news, hopefully soon though it does worry me slightly that there has been a significant period for them to fund raise and in the US market raising funds is normally a fairly quick process...anyway time to watch England GLA
It certainly looks like someone intentionally applied the brakes to 737 development, SOG. Although we'll never know the absolute truth of the matter, you'd hope when negotiating the latest deal that the CPF would try to ensure some level of urgency in moving 737 to the next stage. Perhaps that's just an idealist's point of view though.
On the brighter side, 1801 news must be just about peeking over the horizon - set your sp compass to head north from here!
Good evening HbD,
There was another that did not make sense at the time.
My own opinion is that it were scuppered.
Sierra Oncology stated at the time.e that 737 could prove more commercially viable than Momoletonib.
Developments and then silence. Then we here takeover by GSK.
A year later they hand it back most likely as of the clause within contract requiring return of 737 if no developments in a 12 month period.
Basically they strung it along from the end of 2019 to end of 2022.
3 years!
GSK would certainly not want a competitor to have it as would pose a serious threat to the drugs that were the Tesaro pipeline they paid 5.1 billion for a year earlier.
It will come out one day.
GSK paid billions before due to mal practices.
I have posted much on this subject before.
Hi SOG - no matter how frustrated we punters are with the glacial progress of 737, imagine how Tim & John feel. They must be tearing their hair out.
Taken from the link posted earlier.
Link is from early 2020
NEWS: In a new study, scientists have found that small molecules that stop cancer cells from copying their DNA can boost the effectiveness of another type of cancer drug called CHK1 inhibitors.
This could offer a new, effective way of treating cancer by combining two drugs.
💬 Study co-leader Professor Michelle Garrett, previously a Team Leader at the ICR, explains:
“Our study shows the potential of targeting DNA replication for adding to the effect of an existing drug that blocks a system that helps respond to DNA damage."
I do find it very odd that on this type of news that CHK1 ceased development at the same time as Nick Glover resigned.
Started: Krone, 15 Jun 2024 21:59
Last post: mike001, 16 Jun 2024 14:55
When you analyse these two statements they are actually so open beyond comprehension.
This one was hilarious!
Principle 2 – Seek to understand and meet shareholder needs and expectations.
Sareum is committed to open communication with all its shareholders.
Highlighting great near term potential!
CHAIRMAN'S STATEMENT
Sareum has made good progress during and after this period progressing its lead clinical asset, SDC-1801, through a Phase 1a study. The single ascending dose (SAD) part and the food effect study of SDC-1801 have progressed well, giving the Company continued confidence over the clinical momentum in the trial and optimism as we move towards the completion the study.
The multiple ascending dose (MAD) portion of SDC-1801 is nearing completion. Sareum aims to conclude this part of the trial by the end of Q2 2024. Subject to data review, additional funding and/or potential licencing opportunities, we endeavour to be in a position to commence a Phase 2a study in psoriasis patients before the end of 2024.
It is becoming increasingly clear that the TYK2/JAK1 class offers great potential for the treatment of autoimmune disease, with potential for broad coverage and increased efficacy across key targets, lower toxicity and potentially stronger efficacy. We believe SDC-1801 has the potential to be a best-in-class TYK2/JAK1 inhibitor for autoimmune diseases and we're excited about its progress in this ongoing clinical study. While the MAD study is still in progress, interim data shows that levels of SDC-1801 in blood are already in the expected therapeutic range, and achieve concentrations greater than those predicted to reduce signalling of cytokines dependent on TYK2 and/or JAK1 activity by 50% for a sustained period following once daily oral dosing. Safety data remains blinded, but no serious adverse events have been reported to date.
We were also encouraged that, after the period end, Sareum's co-development partner, the CPF entered into a development and commercialisation license agreement for SRA737 with a private biopharma company based in the US. We are delighted that a partner has been identified to take this molecule forward into further development.
Started: The-Oracle, 15 Jun 2024 09:03
Last post: The-Oracle, 15 Jun 2024 09:03
Small delay here and there, matters not. Quality of the results, Yes. The big fish are watching.
Everything so far appears to be fine, plus I am always encouraged when I think back to Tim and Co taking the initiative, with the hasty set up down under and getting on with a sense of urgency. I want to believe that urgency and spirit is still alive. They have a lot to gain and so do we. Science afterall not funding is where they are in command.
Everyone's waiting for payday, likely the last chance to buy in this low for the rest of your lives. Gla
Started: BasilAlderman, 14 Jun 2024 08:24
Last post: blueandwhite, 15 Jun 2024 01:02
Sorry for delay in response and I agree with what you say. My argument is from my investment point of view, I don’t want it devalued. I know what AIM can do with very little shares and I know the impact of a delay. I pray there isn’t one but if there is, Sareum as you state, should control the narrative correctly. However,I still believe it will come on time as we have not been told otherwise. As an Accountant I struggle to understand the logic of a shares value being massively eroded due to a slight change in time, but it is AIM.
Prob more of a warning to those who may set stops/sell price that may be triggered, just be aware. Our time will come
I recall the last group of MAD candidates for MAD testing re phase 1a was early June. So that is probably complete now. No negative reactions have been reported yet which is encouraging. It is like your team being 1-0 up with only a couple of minutes remaining and time seems to pass slower and slower as you wait for the final whistle!
Blueandwhite- agree with the sentiment. The problem is sareum have set the expectation and rightly so, investors will hold them to it. A delay on the RNS which we all hope will be positive would not be taken well (especially if no reason is given). Agree it’s not in sareums control, but investor relations through timely informative RNS is - 10 days and counting
That was not meant as an attack on anyone. Just been in too many shares on AIM in the past that I won’t be surprised by anything that people do to make a few quid. I remember Rockhopper a few years back, manipulation was rife, never anything done about it. Good luck all
I don’t see the necessity for people to keep mentioning the date that the data is expected. the company are not in control of this. It will come when it comes. Once expectations are made and if not met it only gives the opportunity for people to drive the price down by the traders. Most here have waited for years and so no problem in another few days.
Be careful in this place, manipulation is rife. People setting expectations that may not be achievable. Good luck all
Started: AliceBeagle, 14 Jun 2024 15:42
Last post: Lsesar, 14 Jun 2024 22:24
2.5% down says there were more sold than bought - not bothered about if a particular sell was actually a buy
Most of the apparent sells were buys. I bought 30,000 and went through at the 38p the selling price. Don’t be fooled by mm antics. Nice weekend all. ;+)
Delayed buy of 26k is the reason MM did not want to drop the bid
Sells by definition of mid buy and sell.
I bought a few at 37.94,
A waiting game at the moment.
Decent news needs to follow on from phase 1a clinical trial results.
No serious adverse events which is no surprise.
Really odd day - 43 trades, most of them sells and some quite big sells and still only 2.65% down. Very happy we are not down even more but quite an odd day!
Started: colbaltblue, 14 Jun 2024 16:33
Last post: colbaltblue, 14 Jun 2024 16:33
And not a hint of FOMO!
Started: Lsesar, 14 Jun 2024 13:09
Last post: Lsesar, 14 Jun 2024 13:09
…*Assumption being it being processed in Australia
If the report is being number crunched and finalised it is unlikely that we will get an RNS in the after noon, and due to the time difference would be more likely a standard 730am notification- I’ve stopped looking for the red dot beyond the early morning
Last post: AndytheMKDon, 14 Jun 2024 11:46
Good morning Leggster. Interesting thing is I just moved some more of my holdings to an ISA and the buy and sell both went through at 38p even though these were open market transactions and not a bed and ISA. So why can you currently buy and sell at exactly the same price?? Not really sure I have the answer. Gla. Andy. ;+)
Hmmn not really a believer in the codes theory but 3 buys of 2 shares, in the code theory isn't 2 I need shares badly but don't take the price down?
GLA